AR117943A1 - Combinaciones de lípidos - Google Patents

Combinaciones de lípidos

Info

Publication number
AR117943A1
AR117943A1 ARP180103836A ARP180103836A AR117943A1 AR 117943 A1 AR117943 A1 AR 117943A1 AR P180103836 A ARP180103836 A AR P180103836A AR P180103836 A ARP180103836 A AR P180103836A AR 117943 A1 AR117943 A1 AR 117943A1
Authority
AR
Argentina
Prior art keywords
lipids
mussel
combinations
krill
compositions
Prior art date
Application number
ARP180103836A
Other languages
English (en)
Inventor
Christopher Oliver
Stephen Myers
Charles Hodgson
Original Assignee
Pharmalink International Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=66993218&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR117943(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from AU2017905181A external-priority patent/AU2017905181A0/en
Application filed by Pharmalink International Ltd filed Critical Pharmalink International Ltd
Publication of AR117943A1 publication Critical patent/AR117943A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/618—Molluscs, e.g. fresh-water molluscs, oysters, clams, squids, octopus, cuttlefish, snails or slugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/612—Crustaceans, e.g. crabs, lobsters, shrimps, krill or crayfish; Barnacles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11B—PRODUCING, e.g. BY PRESSING RAW MATERIALS OR BY EXTRACTION FROM WASTE MATERIALS, REFINING OR PRESERVING FATS, FATTY SUBSTANCES, e.g. LANOLIN, FATTY OILS OR WAXES; ESSENTIAL OILS; PERFUMES
    • C11B1/00—Production of fats or fatty oils from raw materials
    • C11B1/10—Production of fats or fatty oils from raw materials by extracting
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Insects & Arthropods (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Zoology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

La presente se relaciona en general con combinaciones de lípidos marinos. En particular se relaciona con una combinación de lípidos marinos obtenidos de Perna canaliculus y kril, composiciones y preparaciones que comprenden dichas combinaciones y el uso terapéutico de dichas combinaciones y composiciones. También se describen procesos para la elaboración de aceites de kril y su uso en las combinaciones y composiciones. Reivindicación 1: Una combinación que comprende lípidos de mejillones y aceite de kril, donde la combinación es apta para su administración separada o consecutiva. Reivindicación 25: Una composición que comprende lípidos de mejillón y aceite de kril. Reivindicación 27: La composición según la reivindicación 25 ó 26, donde los lípidos de mejillón adoptan la forma de un extracto lipídico de mejillón que opcionalmente contiene vitamina E. Reivindicación 34: La composición según la reivindicación 32 ó 33, que comprende aproximadamente 10 - 500 mg de lípidos de mejillón y aceite de kril combinados. Reivindicación 41: Un agente combinado para tratar la inflamación, que comprende lípidos de mejillón y aceite de kril.
ARP180103836A 2017-12-22 2018-12-21 Combinaciones de lípidos AR117943A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AU2017905181A AU2017905181A0 (en) 2017-12-22 Lipid combinations

Publications (1)

Publication Number Publication Date
AR117943A1 true AR117943A1 (es) 2021-09-08

Family

ID=66993218

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP180103836A AR117943A1 (es) 2017-12-22 2018-12-21 Combinaciones de lípidos

Country Status (37)

Country Link
US (1) US11654163B2 (es)
EP (1) EP3727404B1 (es)
JP (2) JP2021507872A (es)
KR (1) KR20200102914A (es)
CN (1) CN110337300A (es)
AR (1) AR117943A1 (es)
AU (2) AU2018392997A1 (es)
BR (1) BR112020012770A2 (es)
CA (1) CA3065174A1 (es)
CL (1) CL2020001649A1 (es)
DK (1) DK3727404T3 (es)
DO (1) DOP2020000131A (es)
EA (1) EA202091551A1 (es)
EC (1) ECSP20042134A (es)
ES (1) ES2959633T3 (es)
FI (1) FI3727404T3 (es)
HR (1) HRP20231254T1 (es)
HU (1) HUE064489T2 (es)
IL (1) IL275583B1 (es)
JO (1) JOP20200108B1 (es)
LT (1) LT3727404T (es)
MX (1) MX2019014252A (es)
NI (1) NI202000047A (es)
NZ (1) NZ755776A (es)
PE (1) PE20211308A1 (es)
PH (1) PH12020550965A1 (es)
PL (1) PL3727404T3 (es)
PT (1) PT3727404T (es)
RS (1) RS64705B1 (es)
SA (1) SA520412019B1 (es)
SG (1) SG11202003935QA (es)
SI (1) SI3727404T1 (es)
TW (1) TWI815840B (es)
UA (1) UA126417C2 (es)
UY (1) UY38033A (es)
WO (1) WO2019123400A1 (es)
ZA (1) ZA202003454B (es)

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPN531195A0 (en) * 1995-09-11 1995-10-05 J.W. Broadbent Nominees Pty. Ltd. Lipid extract having anti-inflamatory activity
CA2251265A1 (en) 1998-10-21 2000-04-21 Universite De Sherbrooke Process for lipid extraction of aquatic animal tissues producing a dehydrated residue
US6596303B1 (en) * 1999-03-22 2003-07-22 Mars Incorporated Pet food for maintenance of joint health and alleviation of arthritic symptoms in companion animals
CN1516592A (zh) 2001-06-18 2004-07-28 �����Ǽ���&������Դ���޹�˾ 用于预防和/或治疗心血管疾病、关节炎、皮肤癌、糖尿病、经前综合症和透皮转运的磷虾和/或海产提取物
US8030348B2 (en) * 2001-07-27 2011-10-04 Neptune Technologies & Bioressources, Inc. Natural marine source phospholipids comprising polyunsaturated fatty acids and their applications
ATE413447T1 (de) 2004-01-30 2008-11-15 Bionovate Ltd Lösungsmittelextraktion von lipiden aus perna canaliculus
GB0411166D0 (en) * 2004-05-19 2004-06-23 Bionovate Ltd Treatment for asthma and arthritis
NZ563125A (en) 2005-06-03 2009-11-27 Mcfarlane Marketing Aust Pty L Lipid extract of mussels and method for preparation thereof
TW200811280A (en) 2006-04-20 2008-03-01 Owen John Catchpole Product and process
NZ547429A (en) 2006-05-24 2009-09-25 Ind Res Ltd Extraction of highly unsaturated lipids with liquid dimethyl ether
WO2008035756A1 (fr) * 2006-09-22 2008-03-27 Heimat Co., Ltd. Composition anti-angiogénique comportant un extrait ayant une activité anti-angiogénique et une lécithine
EP2144618B1 (en) * 2007-03-28 2013-05-15 Aker Biomarine ASA Bioeffective krill oil compositions
AU2011213836B2 (en) * 2007-03-28 2013-11-14 Aker Biomarine Antarctic As Bioeffective krill oil compositions
US8557297B2 (en) * 2008-09-12 2013-10-15 Olympic Seafood, As Method for processing crustaceans and products thereof
US8557275B2 (en) * 2009-07-23 2013-10-15 U.S. Nutraceuticals, LLC Composition and method to alleviate joint pain using a mixture of fish oil and fish oil derived, choline based, phospholipid bound fatty acid mixture including polyunsaturated EPA and DHA
US8481072B2 (en) 2009-07-23 2013-07-09 U.S. Nutraceuticals, LLC Composition and method to alleviate joint pain
NZ600167A (en) * 2009-10-29 2014-06-27 Acasti Pharma Inc Concentrated therapeutic phospholipid compositions
KR101616446B1 (ko) 2009-10-30 2016-04-28 샤로스 리미티드 인지질과 중성 지질이 풍부한 크릴 오일을 용매를 사용하지 않고 생산하는 방법
US9415035B2 (en) 2010-09-17 2016-08-16 Maine Natural Health Company, Inc. Compositions containing omega-3 oil with an anti-inflammatory agent and uses thereof
US20120231087A1 (en) * 2011-03-07 2012-09-13 Olympic Seafood Compositions And Methods for Nutritional Supplementation
AU2012242355B2 (en) 2011-04-14 2015-08-20 Polar Omega A/S A process for the isolation of a phospholipid
WO2013052587A2 (en) 2011-10-04 2013-04-11 Wake Forest University Health Sciences Methods for identifying and treating an individual with an inflammatory disease using fatty acid-based therapies
RU2526826C2 (ru) 2012-10-24 2014-08-27 Николай Владимирович Соловьёв Композиция для парентерального введения, способ получения и применение композиции
GB201400431D0 (en) 2014-01-10 2014-02-26 Aker Biomarine As Phospholipid compositions and their preparation
GB201402450D0 (en) 2014-02-12 2014-03-26 Aker Biomarine As Liquid phospholipid-containing compositions for preperation of pharmaceuticals
KR20160144388A (ko) 2014-03-18 2016-12-16 유.에스. 뉴트라수티칼스, 엘.엘.씨. 저분자량 히알루론산 및 아스타잔틴을 사용하여 관절 통증을 완화하기 위한 조성물 및 방법
US10463699B2 (en) 2016-04-04 2019-11-05 Omeza LLC Fish oil topical composition
CN105685482A (zh) 2016-04-21 2016-06-22 中国海洋大学 一种提高石斑鱼稚鱼抗应激能力的微颗粒饲料
CN106306554B (zh) 2016-08-16 2019-10-11 中国水产科学研究院黄海水产研究所 一种可替代鲜活饵料的凡纳滨对虾亲虾饲料
CN111432654A (zh) 2017-12-04 2020-07-17 雾凇科技有限公司 从甲壳类捕获物中生产蛋白质磷脂复合物的方法

Also Published As

Publication number Publication date
IL275583A (en) 2020-08-31
CN110337300A (zh) 2019-10-15
SI3727404T1 (sl) 2023-12-29
DOP2020000131A (es) 2021-02-15
UA126417C2 (uk) 2022-09-28
UY38033A (es) 2019-06-28
TW201929876A (zh) 2019-08-01
IL275583B1 (en) 2024-05-01
EP3727404B1 (en) 2023-08-30
CA3065174A1 (en) 2019-06-27
EA202091551A1 (ru) 2020-11-13
EP3727404A4 (en) 2021-09-01
NI202000047A (es) 2020-09-24
ES2959633T3 (es) 2024-02-27
KR20200102914A (ko) 2020-09-01
PE20211308A1 (es) 2021-07-20
US11654163B2 (en) 2023-05-23
PL3727404T3 (pl) 2024-01-29
JP2021507872A (ja) 2021-02-25
FI3727404T3 (fi) 2023-10-17
NZ755776A (en) 2020-05-29
ZA202003454B (en) 2024-04-24
HRP20231254T1 (hr) 2024-02-02
TWI815840B (zh) 2023-09-21
WO2019123400A9 (en) 2020-01-23
AU2018392997A1 (en) 2019-08-15
ECSP20042134A (es) 2020-12-31
AU2021204787A1 (en) 2021-08-05
LT3727404T (lt) 2023-10-25
PH12020550965A1 (en) 2021-04-26
JOP20200108B1 (ar) 2023-09-17
SG11202003935QA (en) 2020-05-28
RS64705B1 (sr) 2023-11-30
HUE064489T2 (hu) 2024-03-28
US20200093867A1 (en) 2020-03-26
BR112020012770A2 (pt) 2020-12-01
DK3727404T3 (da) 2023-10-09
PT3727404T (pt) 2023-09-28
CL2020001649A1 (es) 2020-11-13
AU2021204787B2 (en) 2023-10-12
EP3727404A1 (en) 2020-10-28
SA520412019B1 (ar) 2022-11-01
MX2019014252A (es) 2020-08-03
JOP20200108A1 (ar) 2020-05-06
JP2023113819A (ja) 2023-08-16
WO2019123400A1 (en) 2019-06-27

Similar Documents

Publication Publication Date Title
ECSP19010079A (es) 3-metil pirazinas 2,5-disustituidas y 3-metil pirazinas 2,5,6-trisustituidas como inhibidores alostéricos de shp2
CL2019000821A1 (es) Composiciones, métodos y usos para inhibir la actividad arginasa. (divisional solicitud 201801134)
CL2019001686A1 (es) Composiciones de aminoácidos y métodos de tratamiento de enfermedades hepáticas.
ECSP17057848A (es) Composiciones farmacéuticas para terapia combinada
AR100562A1 (es) Composición farmacéutica de estradiol y progesterona para terapia de reemplazo hormonal
CL2020000220A1 (es) Composiciones que comprenden aminoácidos para su uso en el tratamiento de enfermedades relacionadas con la disfunción mitocondrial.
ECSP14012527A (es) Composiciones enriquecidas con dpa de ácidos grasos omega 3 poliinsaturados en forma de ácido libre
CL2021001395A1 (es) Compuestos derivados de panteteínas cíclicas; composición farmacéutica que los comprende; y su uso para aumentar las concentraciones de acetil-coa, para el tratamiento de cáncer, enfermedad inflamatoria, enfermedad neurodegenerativa, esclerosis múltiple, entre otras enfermedades.
AR105237A1 (es) Método y composiciones nutricionales que contienen fosfatidiletanolamina, esfingomielina y ácido docosahexaenoico
CO2020010193A2 (es) Una composición farmacéutica para la anemia
AR102780A1 (es) Composiciones farmacéuticas, su preparación y sus usos
CL2017000475A1 (es) Composición para formulación cosmética que consiste en una mezcla de hasta 3 componentes seleccionados de manteca de murumuru, manteca de ucuuba, aceite de nuez de brasil, aceite de maracuyá, manteca de copoazú, aceite de acai y aceite de andiroba y/o ésteres de los mismos; producto cosmético.
CO6540004A2 (es) Métodos y composiciones para el tratamiento rápido de otitis externa
CO2021014835A2 (es) Ácidos grasos poliinsaturados de cadena muy larga, derivados hidroxilados elovanoides y métodos de uso
CL2019002514A1 (es) Composiciones cosméticas para el cuidado de la piel.
AR112466A1 (es) Complejo cosmético para la hidratación bioactiva, composición cosmética, uso y método
TR201903470T4 (tr) Kişisel hijyen için formülasyon.
AR118625A1 (es) Composición cosmética tópica y usos de la misma
AR117943A1 (es) Combinaciones de lípidos
CL2020002644A1 (es) Composición para modular genes responsables de las funciones generales de la piel, que comprende la combinación de un extracto de hymenaea courbaril y una mezcla de cocoilaminoácidos de sodio y sarcosina y aspartato de potasio y aspartato de magnesio (divisional de la solicitud 03354-2018)
CL2021000660A1 (es) Compuestos quelantes de hierro para tratar condiciones estéticas de la piel
CL2020000221A1 (es) Composiciones que comprenden aminoácidos para su uso en el tratamiento de enfermedades relacionadas con la disfunción mitocondrial.
CL2019001131A1 (es) Inhibidor de aldosterona sintasa.
BR112019017314A2 (pt) composições farmacêuticas para terapia de combinação
AR107195A1 (es) Composición lípida vegetal para promover el crecimiento del cabello, método para promover el crecimiento del cabello y uso de dichos lípidos vegetales